Android app on Google Play

Rosetta Genomics (ROSG) Receives Two U.S. Patents for microRNAs, miRNAs

February 14, 2013 8:32 AM EST Send to a Friend
Get Alerts ROSG Hot Sheet
Trade ROSG Now!
Join SI Premium – FREE
Rosetta Genomics Ltd. (NASDAQ: ROSG) announced that the Company has received two notices of allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Applications 12/661,041 and 12/850,091.

The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover the composition of matter for miR-29c*, as well as sequence variants (90% identical thereto), a vector and a probe comprising the same. miR-29c* is a core element in the Company's lead commercial product, miRview® mets2 diagnostic assay for the identification of the tumor of origin in Cancer of Unknown and Uncertain Primary ("CUP").

The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs and Uses Thereof," cover the composition of matter for herpes simplex virus 1 miR-H3, miR-H4 and miR-H5, as well as sequence variants (80% identical thereto), a vector and a complementary sequence comprising the same.




You May Also Be Interested In


Related Categories

Corporate News, Litigation

Add Your Comment